



CryoLife to Present at C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference in New York

October 20, 2005

ATLANTA, Oct. 20 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, today announced that it is scheduled to participate in the C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference at The Palace Hotel in New York City on Tuesday, October 25, 2005.

Steven G. Anderson, President and CEO of CryoLife, Inc., will deliver the Company's presentation beginning at approximately 4:20 p.m. EDT.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiovascular, vascular, and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels and is CE marked in the European Community and approved in Canada for use in soft tissue repair and approved in Australia for use in vascular and pulmonary sealing and repair. The Company also distributes the CryoLife- O'Brien(R) stentless porcine heart valve and the SG Model #100 vascular graft, which are CE marked for distribution within the European Community.

For additional information about the company, visit CryoLife's web site: <http://www.cryolife.com>.

Contact: D. Ashley Lee
EVP, COO, & CFO
(770) 419-3355

SOURCE CryoLife, Inc.